Farcast Biosciences uses fresh tumor samples to evaluate a tumors response to drug treatment.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/11/2018 | Series B | $73.28MM | $xx.xx | $15.32B | Accel, Northpond Ventures, Ra Capital Management, Sands Capital Ventures, Sequoia Capital | |
Price per Share
$xx.xx
Shares Outstanding
210,180,924
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Accel, Northpond Ventures, Ra Capital Management, Sands Capital Ventures, Sequoia Capital
|
||||||
08/23/2016 | Series A | $911,501.00 | $xx.xx | $7.16B | Accel Partners, Tata Capital | |
Price per Share
$xx.xx
Shares Outstanding
10,304,100
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Accel Partners, Tata Capital
|
||||||
08/23/2016 | Series A1 | $5.61MM | $xx.xx | $7.16B | Accel Partners, Sands Capital, Sequoia Capital, Tata Capital | |
Price per Share
$xx.xx
Shares Outstanding
34,392,300
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Accel Partners, Sands Capital, Sequoia Capital, Tata Capital
|